Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
USAAF Lt Col. James H. Howard of the 356th Fighter Squadron, 354th Fighter Group was awarded the Medal of Honor for his action during a bomber escort mission near Oschersleben, Germany on 11 January 1944, flying P-51B, serial number 43-6315 nicknamed "Ding Hao". Despite being outnumbered, Howard shot down three German planes and continued to defend the bombers even when his guns went out of action and fuel supply became dangerously low. USAAF Maj. William A. Shomo of the 82nd Reconnaissance Squadron, 71st Reconnaissance Group was awarded the Medal of Honor for his action during a mission over Luzon, Philippines on 11 January 1945, flying an F-6D, the armed photo reconnaissance variant of the P-51, serial number 44-14841 nicknamed "Snooks the 5th". On that mission, Shomo shot down seven Japanese planes and became an "ace in a day".
= 0.0546. Next, multiply this value of "K" by the time elapsed between the first and second measures of radioactivity, 19 hours: (0.0546 x 19) = 1.0368. Change the sign, to make it -1.0368, then find the "inverse Ln"; in this case 0.3546. This value is in the denominator of the decay correcting fraction, so it is the same as multiplying the numerator by its inverse (
Herbal teas can be made from any edible plant material, below is a list of common herbal infusions. Some herbal teas are made from plants which contain caffeine, and other herbal infusions may contain other psychoactive compounds. However, many other common herbal teas have not been shown psychoactive properties when compared to placebos, though they may still have some physical effects. Many herbal teas on the market may also be blends which include various herbs or plant parts. These blends may also include additives, like flavorings.
Sources: en.wikipedia.org
== General care == The skin is the largest organ in the human body, protecting against pathogens, irritants, ultraviolet light, and mechanical injury, while also regulating temperature and water release as perspiration. Simple habits like washing and applying lotion may provide benefit, but little is known scientifically about the clinical efficacy of these practices. Skin care routines, even in hospitals and medical facilities, may be based on personal beliefs, preferences, and local circumstances rather than current evidence or best practices.
=== Hyperrelaxinemia === Premature delivery of relaxin is linked to high levels of relaxin in the mother's bloodstream, known as hyperrelaxinemia. This is caused by the impact of relaxin on the cervix, which disrupts the equilibrium in maintaining the structure of cervical connective tissue. Hyperrelaxinemia caused by ovarian stimulation results in an increased rate of the risk of premature labor and preterm birth.
==== Predictors of greater weight loss ==== Patient selection is an important consideration for any weight loss therapy. The present published literature shows either no influence or conflicting results for patient age, sex, starting weight/BMI on weight loss from ESG. Long-term after care programs have demonstrated benefit for sustained weight loss after ESG, with one study showing that patients who continued after care visits following ESG had 20.5% total body weight loss compared to 16.9% total body weight loss in those who dropped out of long-term follow up programs.
Sources: en.wikipedia.org
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography.
== Archaeological investigation == The site was discovered in 1982 when a team led by Francis Pryor carried out a survey of dykes in the area funded by English Heritage. In 1992 Pryor told National Geographic that he "stumbled – literally – upon' Flag Fen 'when he tripped on a piece of wood lying in the bottom of a drainage ditch." Excavation commenced in the Summer of 1984 and by 1990 had revealed vertical and horizontal timbers, animal bones, a bronze dagger and other metal items and fragments, flint implements and 400 potsherds. Further finds included items imported from continental Europe and the oldest surviving wooden wheel found in England, dating from 1300 BC. In 2012 DigVentures ran the world's first crowdfunded excavation, raising £30,000 to enable a three-week excavation at Flag Fen. The site had experienced a 50% decline in visitors since the large-scale English Heritage-funded excavations had finished in 1995. The project's remit was to help revitalise the heritage attraction whilst providing detailed scientific information on the preservation of the waterlogged timbers. The project involved around 250 members of the public from 11 countries, supported by a specialist team including partners from the British Museum, Durham University, Birmingham University, York Archaeological Trust, University College London and English Heritage to assist in the scientific investigations. 130 members of public received hands-on training in archaeological techniques on site and visitor numbers increased by 29% from the previous year.
==== Political disagreements with Donald Trump ==== Newsom and Donald Trump have had a prolonged dispute over governance in California and federal policy. Trump has repeatedly criticized Newsom's handling of wildfires, immigration policies, and the general administration of the state, often using derogatory language. In response, Newsom has made sharply critical statements on social media, including personal insults aimed at Trump in 2025 and 2026.
Mitogen-activated protein kinase 1 (MAPK1) is also known as extracellular signal-regulated kinase 2 (ERK2). Two similar protein kinases with 85% sequence identity were originally called ERK1 and ERK2. They were found during a search for protein kinases that are rapidly phosphorylated after activation of cell surface tyrosine kinases such as the epidermal growth factor receptor. Phosphorylation of ERKs leads to the activation of their kinase activity. The molecular events linking cell surface receptors to activation of ERKs are complex. It was found that Ras GTP-binding proteins are involved in the activation of ERKs. Another protein kinase, Raf-1, was shown to phosphorylate a "MAP kinase-kinase", thus qualifying as a "MAP kinase kinase kinase". The MAP kinase-kinase, which activates ERK, was named "MAPK/ERK kinase" (MEK). Receptor-linked tyrosine kinases, Ras, Raf, MEK, and MAPK could be fitted into a signaling cascade linking an extracellular signal to MAPK activation. See: MAPK/ERK pathway. Transgenic gene knockout mice lacking MAPK1 have major defects in early development. Conditional deletion of Mapk1 in B cells showed a role for MAPK1 in T-cell-dependent antibody production. A dominant gain-of-function mutant of Mapk1 in transgenic mice showed a role for MAPK1 in T-cell development. Conditional inactivation of Mapk1 in neural progenitor cells of the developing cortex lead to a reduction of cortical thickness and reduced proliferation in neural progenitor cells.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.